TG Therapeutics, Inc. (TGTX) — Fair Value Analysis

Base-case fair value (P50): $53.08 · Current price: $48.74 · Verdict: Fairly Valued

The Verdict on TGTX

TG Therapeutics Inc. (TGTX) is currently assessed as Fairly Valued based on our comprehensive Monte Carlo simulations. The current market price of $48.74 aligns closely with our median fair value (P50) target of $53.08. This indicates that, according to our model which runs thousands of forward scenarios, the stock is trading near its intrinsic value. While there is a modest +8.9% potential against the current market price, this falls within the typical range for a fairly valued stock. TGTX's operational and financial health, compared to its sector, is rated as "average," suggesting a balanced risk-reward profile without significant flags for over- or undervaluation from a quality perspective.

How TGTX stacks up against peers

With an "average" quality tier, TGTX demonstrates a standard operational and financial footing relative to its industry peers. This average standing helps to contextualize the Monte Carlo simulation's median fair value (P50) of $53.08. The fact that the market is currently pricing TGTX at $48.74, with a projected +8.9% to our fair value, suggests a consensus view that largely mirrors our simulated median. An average quality rating implies that while the company is stable, it may not possess unique advantages or severe disadvantages that would drastically skew its valuation either upwards or downwards compared to its peer group, reinforcing the "Fairly Valued" verdict.

What this means for investors

For investors, the "Fairly Valued" verdict for TGTX, with a median fair value of $53.08 against a current price of $48.74, suggests that the market has largely priced in the company's current fundamentals and future prospects as modeled. The +8.9% represents the projected room for growth to reach this median fair value. While the median indicates a balanced outlook, Monte Carlo simulations also generate a full distribution of potential outcomes, including various downside and bull-case scenarios for TGTX beyond this P50 target. To explore the full bear and bull distribution and track TGTX's fair value as new fundamentals are released, sign up for a free FairCurve account.